settlement

iStock_000012455703Small
Recently I wrote about how Johnson & Johnson inappropriately marketed Risperdal to treat agitation, confusion and other symptoms in older patients with dementia. As if that's not enough, the company's now tentatively agreeing to a $4 billion - yes, that's  billion - settlement with thousands of patients for whom a company-made hip implant failed.
451px-Risperdal_tablets
We hear a lot about how older Americans have difficulties with their prescription medications. That makes it all the more disturbing when a pharmaceutical company takes advantage of them by promoting a drug as safe and effective for a certain condition - like, say, dementia - when in fact it may not be.
Search AARP Blogs